Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 5/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 10/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836406 | 1.00 | PSMB5 (0.48) | PSMB5PSMB8PTGIRTBXA2ROPRK1 | |
| SCHEMBL21836365 | 0.87 | PSMB5 (0.49) | PSMB5PSMB8PTGIRTBXA2ROPRK1 | |
| SCHEMBL21836367 | 0.87 | PSMB5 (0.49) | PSMB5PSMB8PTGIRTBXA2ROPRK1 | |
| SCHEMBL21836378 | 0.79 | PSMB5 (0.48) | PSMB5PSMB8PTGIRTBXA2RALDH1A1 | |
| SCHEMBL21836380 | 0.79 | PSMB5 (0.48) | PSMB5PSMB8PTGIRTBXA2RALDH1A1 | |
| SCHEMBL21836362 | 0.77 | PIN1 (0.44) | PSMB5ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL21836364 | 0.77 | PIN1 (0.44) | PSMB5ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL21836303 | 0.75 | PSMB5 (0.47) | PSMB5PSMB8PTGIRTBXA2RALDH1A1 | |
| SCHEMBL21836305 | 0.75 | PSMB5 (0.47) | PSMB5PSMB8PTGIRTBXA2RALDH1A1 | |
| SCHEMBL7959352 | 0.75 | PSMB5 (0.51) | PSMB5PSMB8PTGIRTBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PSMB5 293/4885PSMB8 1331/4885PTGIR 3098/4885 |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PSMB5 293/4885PSMB8 1331/4885PTGIR 3098/4885 |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PSMB5 293/4885PSMB8 1331/4885PTGIR 3098/4885 |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PSMB5 293/4885PSMB8 1331/4885PTGIR 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.